Mil95 antibody study for relapsed or refractory cancers
Part of Cancer clinical trials.
This Phase 1 study tests a new antibody drug called MIL95 in people with cancers that have come back or did not respond to prior treatment. It focuses on checking safety and early signs of how well the treatment may work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older
- Your cancer is a relapsed or treatment-resistant lymphoma or solid tumor
- You can do daily activities fairly normally (ECOG 0 or 1)
- You have at least one measurable tumor spot (or an “evaluable” spot the study can track)
- You haven’t had any anti-cancer treatment in the last 4 weeks
- You don’t have certain exclusions, like brain metastases or active serious infections (HIV, hepatitis B/C)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests MIL97, a new treatment, in adults with advanced solid cancers that have come back or cannot be removed. The goal is to find a safe dose and see how the cancer responds.
This early-stage study tests whether MIL62 combined with lenalidomide can shrink or control follicular lymphoma or marginal zone (MZ) lymphoma that has come back or not responded to earlier treatment. It’s designed for adults with measurable disease and enough body strength to take part.
This trial tests whether adding MIL62 to lenalidomide works better than lenalidomide alone in people with follicular lymphoma that no longer responds to rituximab. The goal is to improve tumor control by using an additional medicine along with standard treatment.
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.